Results 21 to 30 of about 265,042 (240)

Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia

Scientific Reports, 2021
The evaluation of the somatic hypermutation of the clonotypic immunoglobulin heavy variable gene has become essential in the therapeutic management in chronic lymphocytic leukemia patients.
Crescenzio Francesco Minervini, Cosimo Cumbo, Immacolata Redavid, Maria Rosa Conserva, Paola Orsini, Antonella Zagaria, Luisa Anelli, Nicoletta Coccaro, Giuseppina Tota, Luciana Impera, Elisa Parciante, Francesco Tarantini, Annamaria Giordano, Giorgina Specchia, Pellegrino Musto, Francesco Albano   +15 more
doaj   +1 more source

Autologous Stem Cell Transplantations

Annals of Medicine, 1996
High-dose treatments with autologous stem cell support have increasingly been used to improve the treatment results of a variety of haematological and nonhaematological malignancies. High-dose treatments cause severe bone marrow injury, which can effectively be rescued with infusion of a sufficient number of stem cells. Stem cells can be collected from
K, Remes, A, Rajamäki
openaire   +2 more sources

The Role of Allogeneic Transplantation in Chronic Myeloid Leukemia in 2023: A Case-Based Concise Review

Hemato, 2023
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), granting patients a life expectancy close to that of the normal population and, in a subset of patients, the possibility to discontinue therapy ...
Mario Tiribelli, Giuseppe Petruzzellis, Giulia Battaglia, Martina Pucillo, Marta Lisa Battista, Michela Cerno, Antonella Geromin, Gabriele Facchin, Umberto Pizzano, Daniela Damiani, Renato Fanin, Francesca Patriarca   +11 more
doaj   +1 more source

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation

Haematologica
We compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo ...
Iryna Lastovytska, Silke Heidenreich, Evgeny Klyuchnikov, Christian Niederwieser, Nico Gagelmann, Johanna Richter, Radwan Massoud, Kristin Rathje, Tetiana Perekhrestenko, Gaby Zeck, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis Ayuk, Nicolaus Kröger   +14 more
doaj   +1 more source

Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia

Haematologica, 2023
Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or with venetoclax (FLAVIDA ...
Rabia Shahswar, Gernot Beutel, Razif Gabdoulline, Adrian Schwarzer, Arnold Kloos, Christian Koenecke, Michael Stadler, Gudrun Gohring, Yvonne Lisa Behrens, Zhixiong Li, Louisa-Kristin Dallmann, Piroska Klement, Catherin Albert, Martin Wichmann, Yasmine Alwie, Axel Benner, Maral Saadati, Arnold Ganser, Felicitas Thol, Michael Heuser   +19 more
doaj   +1 more source

Dexamethasone for Chemotherapy‐Induced Nausea and Vomiting Prevention in Pediatric Patients: International Consensus

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background An international Delphi panel of experts developed consensus statements to delineate the circumstances where the risks of dexamethasone as an antiemetic do and do not outweigh its benefits. Procedure Experts in supportive care of pediatric patients were invited to participate.
Negar Shavandi, Paula D. Robinson, Shana Jacobs, L. Lee Dupuis, the International Pediatric Dexamethasone Panel, Sameer Bakhshi, Tiene Bauters, Eva Brack, Simone Cesaro, Claire Fosbrook, Jason Freedman, Tamara MacDonald, Eloise Neumann, Venkatraman Radhakrishnan, Rod Rassekh, Florian Slimano, Johnathan Soggee, Joel Thompson, Marianne van de Wetering, Milena Villarroel, Jasper Wong   +20 more
wiley   +1 more source

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle, Kiersten Ricci, Kelly Blache, Rebecca A. Marsh, Adrienne M. Hammill, Elissa Engel   +5 more
wiley   +1 more source

The Role of Invasive Procedures in the Treatment of Complicated Gastrointestinal Graft‐Versus‐Host Disease in Pediatric Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Gastrointestinal graft‐versus‐host disease (GI GVHD) following hematopoietic stem cell transplant is typically managed with medical therapy, but surgery and angioembolization may be warranted in selected cases with life‐threatening complications.
Gaia Brunetti, Giorgio Persano, Chiara Grimaldi, Pier Luigi Di Paolo, Carmen Malaspina, Francesco Quagliarella, Valerio Balassone, Anna Chiara Iolanda Contini, Gian Luigi Natali, Rita Alaggio, Ivan Pietro Aloi, Tamara Caldaro, Alessandro Crocoli   +12 more
wiley   +1 more source

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel

Molecular Therapy: Methods & Clinical Development, 2020
Treatment with axicabtagene ciloleucel (Axi-cel) CD19-CAR-T (chimeric antigen receptor T) cells has been approved for refractory/relapsed diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL).
Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A. Ayuk   +7 more
doaj   +1 more source

IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis

Experimental Hematology & Oncology, 2021
Interferon regulatory factor 4 (IRF4) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) and the polarization of anti-inflammatory M2
Cosimo Cumbo, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Immacolata Redavid, Crescenzio Francesco Minervini, Nicoletta Coccaro, Giuseppina Tota, Alessandra Ricco, Elisa Parciante, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto, Francesco Albano   +13 more
doaj   +1 more source